{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:20:27Z","timestamp":1790659227429,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69736-y","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:07:23Z","timestamp":1771240043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GCN5 drives MASLD progression through LXR\u03b1\/SREBP1c signaling pathway\u2013mediated de novo lipogenesis"],"prefix":"10.1038","volume":"17","author":[{"given":"Hai-Tao","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Yue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Xue","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Feng","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8140-4610","authenticated-orcid":false,"given":"Jian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Rong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Na","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-1728","authenticated-orcid":false,"given":"Zu-Guo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"69736_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s42255-024-00985-1","volume":"6","author":"CL Hsu","year":"2024","unstructured":"Hsu, C. L. & Loomba, R. From NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research. Nat. Metab. 6, 600\u2013602 (2024).","journal-title":"Nat. Metab."},{"key":"69736_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi, K. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 7, 851\u2013861 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"69736_CR3","first-page":"1439","volume":"331","author":"E Harris","year":"2024","unstructured":"Harris, E. FDA Okays first drug for scarring from fatty liver disease. JAMA 331, 1439 (2024).","journal-title":"JAMA"},{"key":"69736_CR4","doi-asserted-by":"publisher","first-page":"103910","DOI":"10.1016\/j.drudis.2024.103910","volume":"29","author":"S Wei","year":"2024","unstructured":"Wei, S., Wang, L., Evans, P. C. & Xu, S. NAFLD and NASH: etiology, targets and emerging therapies. Drug Discov. Today 29, 103910 (2024).","journal-title":"Drug Discov. Today"},{"key":"69736_CR5","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1002\/hep.20973","volume":"43","author":"GC Farrell","year":"2006","unstructured":"Farrell, G. C. & Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99\u2013S112 (2006).","journal-title":"Hepatology"},{"key":"69736_CR6","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1210\/jc.2005-2248","volume":"91","author":"DG Haider","year":"2006","unstructured":"Haider, D. G. et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J. Clin. Endocrinol. Metab. 91, 1578\u20131581 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"69736_CR7","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti, E., Pinzani, M. & Tsochatzis, E. A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038\u20131048 (2016).","journal-title":"Metabolism"},{"key":"69736_CR8","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nrgastro.2013.182","volume":"10","author":"QM Anstee","year":"2013","unstructured":"Anstee, Q. M. & Day, C. P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 10, 645\u2013655 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"69736_CR9","doi-asserted-by":"publisher","first-page":"105484","DOI":"10.1016\/j.phrs.2021.105484","volume":"167","author":"N Sodum","year":"2021","unstructured":"Sodum, N., Kumar, G., Bojja, S. L., Kumar, N. & Rao, C. M. Epigenetics in NAFLD\/NASH: Targets and therapy. Pharmacol. Res. 167, 105484 (2021).","journal-title":"Pharmacol. Res."},{"key":"69736_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","volume":"68","author":"M Eslam","year":"2018","unstructured":"Eslam, M., Valenti, L. & Romeo, S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J. Hepatol. 68, 268\u2013279 (2018).","journal-title":"J. Hepatol."},{"key":"69736_CR11","doi-asserted-by":"publisher","first-page":"101111","DOI":"10.1016\/j.molmet.2020.101111","volume":"50","author":"W Jonas","year":"2021","unstructured":"Jonas, W. & Schurmann, A. Genetic and epigenetic factors determining NAFLD risk. Mol. Metab. 50, 101111 (2021).","journal-title":"Mol. Metab."},{"key":"69736_CR12","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"69736_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1677\/JME-08-0025","volume":"41","author":"KM Aagaard-Tillery","year":"2008","unstructured":"Aagaard-Tillery, K. M. et al. Developmental origins of disease and determinants of chromatin structure: maternal diet modifies the primate fetal epigenome. J. Mol. Endocrinol. 41, 91\u2013102 (2008).","journal-title":"J. Mol. Endocrinol."},{"key":"69736_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0959-437X(96)80048-7","volume":"6","author":"JE Brownell","year":"1996","unstructured":"Brownell, J. E. & Allis, C. D. Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Curr. Opin. Genet. Dev. 6, 176\u2013184 (1996).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"69736_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1042\/CS20200986","volume":"135","author":"ME Haque","year":"2021","unstructured":"Haque, M. E. et al. The GCN5: its biological functions and therapeutic potentials. Clin. Sci. 135, 231\u2013257 (2021).","journal-title":"Clin. Sci."},{"key":"69736_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/emboj.2010.318","volume":"30","author":"Q Jin","year":"2011","unstructured":"Jin, Q. et al. Distinct roles of GCN5\/PCAF-mediated H3K9ac and CBP\/p300-mediated H3K18\/27ac in nuclear receptor transactivation. EMBO J. 30, 249\u2013262 (2011).","journal-title":"EMBO J."},{"key":"69736_CR17","doi-asserted-by":"publisher","first-page":"114835","DOI":"10.1016\/j.biopha.2023.114835","volume":"165","author":"HT Xiao","year":"2023","unstructured":"Xiao, H. T., Jin, J. & Zheng, Z. G. Emerging role of GCN5 in human diseases and its therapeutic potential. Biomed. Pharmacother. 165, 114835 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"69736_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejmech.2017.06.009","volume":"138","author":"A Kumar","year":"2017","unstructured":"Kumar, A. et al. Designing novel inhibitors against histone acetyltransferase (HAT: GCN5) of Plasmodium falciparum. Eur. J. Med. Chem. 138, 26\u201337 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"69736_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ejmech.2018.02.005","volume":"151","author":"H Xiong","year":"2018","unstructured":"Xiong, H. et al. Discovery of 1,8-acridinedione derivatives as novel GCN5 inhibitors via high throughput screening. Eur. J. Med. Chem. 151, 740\u2013751 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"69736_CR20","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.molcel.2012.09.030","volume":"48","author":"JE Dominy Jr.","year":"2012","unstructured":"Dominy, J. E. Jr. et al. The deacetylase Sirt6 activates the acetyltransferase GCN5 and suppresses hepatic gluconeogenesis. Mol. Cell 48, 900\u2013913 (2012).","journal-title":"Mol. Cell"},{"key":"69736_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cmet.2006.04.013","volume":"3","author":"C Lerin","year":"2006","unstructured":"Lerin, C. et al. GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. Cell Metab. 3, 429\u2013438 (2006).","journal-title":"Cell Metab."},{"key":"69736_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13147","volume":"7","author":"M Sakai","year":"2016","unstructured":"Sakai, M. et al. The GCN5-CITED2-PKA signalling module controls hepatic glucose metabolism through a cAMP-induced substrate switch. Nat. Commun. 7, 13147 (2016).","journal-title":"Nat. Commun."},{"key":"69736_CR23","doi-asserted-by":"publisher","first-page":"10635","DOI":"10.1074\/jbc.M115.706200","volume":"291","author":"CD Tavares","year":"2016","unstructured":"Tavares, C. D. et al. The methionine transamination pathway controls hepatic glucose metabolism through regulation of the GCN5 acetyltransferase and the PGC-1alpha transcriptional coactivator. J. Biol. Chem. 291, 10635\u201310645 (2016).","journal-title":"J. Biol. Chem."},{"key":"69736_CR24","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1002\/hep.31897","volume":"74","author":"YR Im","year":"2021","unstructured":"Im, Y. R. et al. A systematic review of animal models of NAFLD finds high-fat, high-fructose diets most closely resemble human NAFLD. Hepatology 74, 1884\u20131901 (2021).","journal-title":"Hepatology"},{"key":"69736_CR25","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nrm4074","volume":"16","author":"Y Wang","year":"2015","unstructured":"Wang, Y., Viscarra, J., Kim, S. J. & Sul, H. S. Transcriptional regulation of hepatic lipogenesis. Nat. Rev. Mol. Cell Biol. 16, 678\u2013689 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"69736_CR26","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1042\/BCJ20210071","volume":"478","author":"P Ferre","year":"2021","unstructured":"Ferre, P., Phan, F. & Foufelle, F. SREBP-1c and lipogenesis in the liver: an update1. Biochem. J. 478, 3723\u20133739 (2021).","journal-title":"Biochem. J."},{"key":"69736_CR27","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1101\/gad.844900","volume":"14","author":"JJ Repa","year":"2000","unstructured":"Repa, J. J. et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 14, 2819\u20132830 (2000).","journal-title":"Genes Dev."},{"key":"69736_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/sj.bjp.0707241","volume":"151","author":"CE Leik","year":"2007","unstructured":"Leik, C. E. et al. GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br. J. Pharmacol. 151, 450\u2013456 (2007).","journal-title":"Br. J. Pharmacol."},{"key":"69736_CR29","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1073\/pnas.112059299","volume":"99","author":"SB Joseph","year":"2002","unstructured":"Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99, 7604\u20137609 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69736_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cmet.2016.07.016","volume":"24","author":"TG Kirchgessner","year":"2016","unstructured":"Kirchgessner, T. G. et al. Beneficial and adverse effects of an LXR agonist on human lipid and lipoprotein metabolism and circulating neutrophils. Cell Metab. 24, 223\u2013233 (2016).","journal-title":"Cell Metab."},{"key":"69736_CR31","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1053\/j.gastro.2020.10.008","volume":"160","author":"SO Aseem","year":"2021","unstructured":"Aseem, S. O. et al. Epigenomic evaluation of cholangiocyte transforming growth factor-beta signaling identifies a selective role for histone 3 lysine 9 acetylation in biliary fibrosis. Gastroenterology 160, 889\u2013905.e810 (2021).","journal-title":"Gastroenterology"},{"key":"69736_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13227","volume":"7","author":"M Fournier","year":"2016","unstructured":"Fournier, M. et al. KAT2A\/KAT2B-targeted acetylome reveals a role for PLK4 acetylation in preventing centrosome amplification. Nat. Commun. 7, 13227 (2016).","journal-title":"Nat. Commun."},{"key":"69736_CR33","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s42255-022-00700-y","volume":"4","author":"S Gallage","year":"2022","unstructured":"Gallage, S. et al. A researcher\u2019s guide to preclinical mouse NASH models. Nat. Metab. 4, 1632\u20131649 (2022).","journal-title":"Nat. Metab."},{"key":"69736_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","volume":"8","author":"L Hebbard","year":"2011","unstructured":"Hebbard, L. & George, J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8, 35\u201344 (2011).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"69736_CR35","doi-asserted-by":"publisher","first-page":"332","DOI":"10.14218\/JCTH.2017.00061","volume":"6","author":"A Moslehi","year":"2018","unstructured":"Moslehi, A. & Hamidi-Zad, Z. Role of SREBPs in liver diseases: a mini-review. J. Clin. Transl. Hepatol. 6, 332\u2013338 (2018).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"69736_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrendo.2017.91","volume":"13","author":"H Shimano","year":"2017","unstructured":"Shimano, H. & Sato, R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat. Rev. Endocrinol. 13, 710\u2013730 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"69736_CR37","doi-asserted-by":"publisher","first-page":"30028","DOI":"10.1074\/jbc.274.42.30028","volume":"274","author":"I Shimomura","year":"1999","unstructured":"Shimomura, I., Bashmakov, Y. & Horton, J. D. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274, 30028\u201330032 (1999).","journal-title":"J. Biol. Chem."},{"key":"69736_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cmet.2011.12.017","volume":"15","author":"YA Moon","year":"2012","unstructured":"Moon, Y. A. et al. The Scap\/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 15, 240\u2013246 (2012).","journal-title":"Cell Metab."},{"key":"69736_CR39","doi-asserted-by":"publisher","first-page":"52772","DOI":"10.1074\/jbc.M410302200","volume":"279","author":"CM Adams","year":"2004","unstructured":"Adams, C. M. et al. Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. J. Biol. Chem. 279, 52772\u201352780 (2004).","journal-title":"J. Biol. Chem."},{"key":"69736_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cmet.2010.12.004","volume":"13","author":"JJ Tang","year":"2011","unstructured":"Tang, J. J. et al. Inhibition of SREBP by a small molecule, betulin, improves hyperlipidemia and insulin resistance and reduces atherosclerotic plaques. Cell Metab. 13, 44\u201356 (2011).","journal-title":"Cell Metab."},{"key":"69736_CR41","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1080\/15548627.2020.1757955","volume":"17","author":"ZG Zheng","year":"2021","unstructured":"Zheng, Z. G. et al. Discovery of a potent SCAP degrader that ameliorates HFD-induced obesity, hyperlipidemia and insulin resistance via an autophagy-independent lysosomal pathway. Autophagy 17, 1592\u20131613 (2021).","journal-title":"Autophagy"},{"key":"69736_CR42","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/CIRCRESAHA.110.226878","volume":"108","author":"SS Im","year":"2011","unstructured":"Im, S. S. & Osborne, T. F. Liver x receptors in atherosclerosis and inflammation. Circ. Res. 108, 996\u20131001 (2011).","journal-title":"Circ. Res."},{"key":"69736_CR43","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1172\/JCI59817","volume":"122","author":"Y Zhang","year":"2012","unstructured":"Zhang, Y. et al. Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J. Clin. Invest. 122, 1688\u20131699 (2012).","journal-title":"J. Clin. Invest."},{"key":"69736_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nm820","volume":"9","author":"SB Joseph","year":"2003","unstructured":"Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J. & Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9, 213\u2013219 (2003).","journal-title":"Nat. Med."},{"key":"69736_CR45","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1872-034X.2008.00382.x","volume":"38","author":"N Higuchi","year":"2008","unstructured":"Higuchi, N. et al. Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatol. Res. 38, 1122\u20131129 (2008).","journal-title":"Hepatol. Res."},{"key":"69736_CR46","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1074\/jbc.M111421200","volume":"277","author":"G Liang","year":"2002","unstructured":"Liang, G. et al. Diminished hepatic response to fasting\/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J. Biol. Chem. 277, 9520\u20139528 (2002).","journal-title":"J. Biol. Chem."},{"key":"69736_CR47","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41574-018-0037-x","volume":"14","author":"B Wang","year":"2018","unstructured":"Wang, B. & Tontonoz, P. Liver X receptors in lipid signalling and membrane homeostasis. Nat. Rev. Endocrinol. 14, 452\u2013463 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"69736_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1172\/JCI73615","volume":"125","author":"GH Kim","year":"2015","unstructured":"Kim, G. H. et al. Hepatic TRAP80 selectively regulates lipogenic activity of liver X receptor. J. Clin. Invest. 125, 183\u2013193 (2015).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69736-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69736-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69736-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:05:29Z","timestamp":1774541129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69736-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69736"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69736-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5166860\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2821"}}